Inventor · disambiguated record
Roy M. Pollock
Also filed as: POLLOCK ROY M · POLLOCK ROY MACFARLANE
13 granted patents·22 pending applications·229 citations·filing 2001–2025
93Inventor score
Files withEPIZYME INC31ARIAD GENE THERAPEUTICS INC1C4 THERAPEUTICS INC1COPELAND ROBERT A1OLHAVA EDWARD JAMES1
Top patents by PatentIndex Score
35 records- 0196US8691507B2Inhibitors of human EZH2 and methods of use thereofEPIZYME INC·Filed 2013·Granted Apr 8, 2014·40 cites·12 claims
- 0295US9446064B2Combination therapy for treating cancerEPIZYME INC·Filed 2014·Granted Sep 20, 2016·22 cites·23 claims
- 0394US9333217B2Inhibitors of human EZH2, and methods of use thereofEPIZYME INC·Filed 2014·Granted May 10, 2016·23 cites·6 claims
- 0494US8580762B2Substituted purine and 7-deazapurine compoundsOLHAVA EDWARD JAMES·Filed 2011·Granted Nov 12, 2013·37 cites·6 claims
- 0593US10525074B2Combination therapy for treating cancerEPIZYME INC·Filed 2016·Granted Jan 7, 2020·7 cites·23 claims
- 0693US10112968B2Inhibitors of protein methyltransferase DOT1L and methods of use thereofEPIZYME INC·Filed 2016·Granted Oct 30, 2018·5 cites·14 claims
- 0793US9096634B2Substituted purine and 7-deazapurine compoundsEPIZYME INC·Filed 2013·Granted Aug 4, 2015·17 cites·20 claims
- 0893US8895245B2Inhibitors of human EZH2 and methods of use thereofCOPELAND ROBERT A·Filed 2011·Granted Nov 25, 2014·42 cites·8 claims
- 0992US10881680B2Method of treating leukemiaEPIZYME INC·Filed 2018·Granted Jan 5, 2021·3 cites·20 claims
- 1092US9949999B2Inhibitors of human EZH2, and methods of use thereofEPIZYME INC·Filed 2016·Granted Apr 24, 2018·10 cites·17 claims
- 1192US9597348B2Method of treating leukemiaEPIZYME INC·Filed 2013·Granted Mar 21, 2017·15 cites·18 claims
- 1289US10143704B2Methods for treating cancerEPIZYME INC·Filed 2014·Granted Dec 4, 2018·8 cites·19 claims
- 1374US11633420B2Method of treating leukemiaEPIZYME INC·Filed 2021·Granted Apr 25, 2023·0 cites·13 claims
- 1473US2020397812A1Inhibitors of human ezh2, and methods of use thereofEPIZYME INC·Filed 2020·Application pending·0 cites
- 1571US2021252035A1Substituted purine and 7-deazapurine compoundsEPIZYME INC·Filed 2020·Application pending·0 cites
- 1665US2015284422A1Inhibitors of protein methyltransferase dot1l and methods of use thereofEPIZYME INC·Filed 2013·Application pending·0 cites
- 1765US2020016162A1Inhibitors of human ezh2, and methods of use thereofEPIZYME INC·Filed 2019·Application pending·0 cites
- 1864US2020113923A1Dot1l inhibitors for use in the treatment of leukemiaEPIZYME INC·Filed 2019·Application pending·0 cites
- 1963US2018271892A1Inhibitors of human ezh2, and methods of use thereofEPIZYME INC·Filed 2018·Application pending·0 cites
- 2061US2018280422A1Substituted purine and 7-deazapurine compoundsEPIZYME INC·Filed 2017·Application pending·0 cites
- 2161US2020009176A1Treatment of leukemia via the administration of dot1l inhibitor pinometostatEPIZYME INC·Filed 2019·Application pending·0 cites
- 2260US2018243315A1Inhibitors of human ezh2, and methods of use thereofEPIZYME INC·Filed 2017·Application pending·0 cites
- 2360US2020030355A1Combination therapy for treating cancerEPIZYME INC·Filed 2019·Application pending·0 cites
- 2460US2019100552A1Inhibitors of protein methyltransferase dot1l and methods of use thereofEPIZYME INC·Filed 2018·Application pending·0 cites
- 2556US2017065600A1Inhibitors of human ezh2, and methods of use thereofEPIZYME INC·Filed 2016·Application pending·0 cites
- 2656US2017165288A1Method of treating leukemiaEPIZYME INC·Filed 2016·Application pending·0 cites
- 2755US2015366893A1Substituted purine and 7-deazapurine compoundsEPIZYME INC·Filed 2015·Application pending·0 cites
- 2852US2016045531A1Combination therapy for treating cancerEPIZYME INC·Filed 2014·Application pending·0 cites
- 2951US2019076455A1Treatment of leukemia via the administration of dot1l inhibitor pinometostatEPIZYME INC·Filed 2015·Application pending·0 cites
- 3051US2017232030A1Combination therapy for treating cancerEPIZYME INC·Filed 2015·Application pending·0 cites
- 3151US2015342979A1Dot1l inhibitors for use in the treatment of leukemiaEPIZYME INC·Filed 2013·Application pending·0 cites
- 3250US2025289827A1Morphic forms of a mutant braf degrader and methods of manufacture thereofC4 THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 3344US2002048792A1Methods and materials for regulated production of proteinsARIAD GENE THERAPEUTICS INC·Filed 2001·Application pending·0 cites
- 3441US2018028552A1Combination therapy for treating cancerEPIZYME INC·Filed 2016·Application pending·0 cites
- 3540US2019083521A1Combination therapy for treating cancerEPIZYME INC·Filed 2015·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →